CYC
Cyclopharm Limited
🇦🇺 ASX
🩺 HEALTH CARE
👑 Overview
📈 Performance
💰 Dividends
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-4.71%
Annual Growth
5 years average annual capital growth
💰
0.42%
Annual dividend yield
Based on the most recent dividend
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
13
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in diagnostic imaging in lung health. The firm's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The firm uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. The firm distributes its products in approximately 65 countries.
📈 Performance
Price History
+157.05%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💰 Dividends
Payouts
💰 Annual Dividend Yield*
0.42%
💰 Annual Dividend Earnings Per $1,000 invested**
$4.17
💰 Most Recent Dividend Franked Percentage Estimate
0.00%
💰 Average Dividend Franked Percentage Estimate
82.00 %
💰 Dividend reinvestment
* Based on the most recent dividend
** Calculated by multiplying the most recent dividend yield by $1,000
Estimate your dividend
If you held
$
of CYC, your last dividend payment(s) would have been:
$ 20.83
on Mon Sep 11 2023
$ 33.33
on Tue Apr 04 2023
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Dividend History
1Y
5Y
10Y
Graph
Table
Year
Yearly Dividend Earnings Per Share
Franking Estimate
2025
$0.00
0.00%
2024
$0.00
0.00%
2023
$0.01
0.00%
2022
$0.01
0.00%
2021
$0.01
0.00%
2020
$0.01
0.00%
2019
$0.01
0.00%
2018
$0.01
0.00%
2017
$0.01
0.00%
2016
$0.01
0.00%
💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$1.07
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in CYC
13
📊 Total Capital Earnings
$17K
🔃 Average investment frequency
23 weeks
💵 Average investment amount
$2,238
⏰ Last time a customer invested in CYC
26 days
CYC investor breakdown
💵 Income of investors
More than 200k
150k - 200k
8%
100k - 150k
23%
50k - 100k
38%
Less than 50k
31%
👶 Age of investors
18 - 25
15%
26 - 34
23%
35 - 90
62%
🙋 Legal gender of investors
Female
62%
Male
38%
Pearlers who invest in CYC also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
9.25%
📊 Share price
$96.77 AUD
🇦🇺 AUSTRALIA
🧱 MATERIALS
💸 FINANCIALS
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
17.78%
📊 Share price
$55.94 AUD
📈 HIGH PRICE GROWTH
💰 HIGH DIVIDEND
🇺🇸 UNITED STATES
Telix Pharmaceuticals Limited.engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The firm is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. The company develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. The company operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.
🙌 Performance (5Yr p.a)
426.78%
📊 Share price
$25.69 AUD
🧬 BIOTECHNOLOGY
Pro Medicus Ltd. provides a range of radiology information technology software and services to hospitals, imaging centers and health care groups. The company is headquartered in Richmond, Victoria. The company went IPO on 2000-10-10. The firm provides a full range of medical imaging software and services to hospitals, imaging centers and health care groups in Australia, North America and Europe. Its products include Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro and Visage Ease. Its Visage RIS is a radiology information systems (RIS) medical software for practicing of management, training, installation and professional services. Visage RIS capabilities include patient registration, billing, scheduling, typing, HL7 integration, financial reporting, digital dictation and voice recognition integration. Its Visage 7.0 is a healthcare imaging software that provides clinicians with visualization capability for rapidly viewing 2-D, 3-D and 4-D medical images and picture archive and communication system (PACS)/digital imaging software that is sold directly and to original equipment manufacturers (OEM), training, installation and others.
🙌 Performance (5Yr p.a)
151.00%
📊 Share price
$207.17 AUD
🩺 HEALTH CARE
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
13.88%
📊 Share price
$127.58 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
Want more shares? Try these...
